{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:40:00Z","timestamp":1791830400573,"version":"4.3.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>The overall kidney survival among lupus nephritis patients has improved with currently used induction immunosuppression regimens of corticosteroids and either cyclophosphamide or mycophenolate mofetil; however, there still remains a significant number of lupus nephritis patients who do not achieve remission with these regimens. Investigators have looked at other immunosuppressive regimens for lupus nephritis, and there has been interest in the use of calcineurin inhibitors in this regard. Calcineurin inhibitors are potentially an attractive option because of their established ability to inhibit T cell function, attenuate proteinuria through non-immunologic means, and their safety in pregnancy and lactation. In this review, we discuss the findings and limitations of selected trials that evaluated the use of calcineurin inhibitors in the treatment of lupus nephritis, either with corticosteroids alone or as a component of multitarget therapy when combined with mycophenolate mofetil. There may be a role for calcineurin inhibitors among patients with heavy proteinuria, as well as younger patients with refractory lupus nephritis. The multitarget therapy trials reveal higher rates of remission compared with mycophenolate mofetil alone and cyclophosphamide; however, some trials highlight the possibility of more infectious adverse events. We discuss the need for further study of calcineurin inhibitors in more diverse patient populations and the need for trials with longer follow-up with \u201chard\u201d endpoints beyond proteinuria reduction, such as worsening CKD or repeat protocol biopsies, given the calcineurin inhibitors ability to reduce proteinuria non-immunologically and thus increased rate of relapse when the drug is tapered. While there may indeed be a space for calcineurin inhibitors to help increase remission rates in lupus nephritis patients, more work is needed to help address the questions the studies available to date have yet to answer.<\/jats:p>","DOI":"10.2215\/cjn.13761119","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T14:55:20Z","timestamp":1583765720000},"page":"1066-1072","source":"Crossref","is-referenced-by-count":36,"title":["The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis"],"prefix":"10.2215","volume":"15","author":[{"given":"Yonatan","family":"Peleg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Bomback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/j.ajkd.2018.07.007","article-title":"An update on therapies for proliferative lupus nephritis: How certain can we be about the evidence?","volume":"72","author":"Bomback","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis","volume":"62","author":"Beck","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.berh.2017.09.010","article-title":"Calcineurin inhibitors in systemic lupus erythematosus","volume":"31","author":"Mok","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00467-010-1469-2","article-title":"Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies","volume":"25","author":"Bensman","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203310371155","article-title":"Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: The Cyclofa-Lune study","volume":"19","author":"Zavada","year":"2010","journal-title":"Lupus"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2215\/CJN.02271205","article-title":"A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years","volume":"1","author":"Moroni","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/ndt\/gfr484","article-title":"Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis","volume":"27","author":"Li","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: A randomised controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00296-018-4154-6","article-title":"Long-term effects of tacrolimus for maintenance therapy of lupus nephritis: A 5-year retrospective study at a single center","volume":"38","author":"Karasawa","year":"2018","journal-title":"Rheumatol Int"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1440-1797.2012.01574.x","article-title":"Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome","volume":"17","author":"Yap","year":"2012","journal-title":"Nephrology (Carlton)"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1681\/ASN.2007121272","article-title":"Successful treatment of class V+IV lupus nephritis with multitarget therapy","volume":"19","author":"Bao","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: A randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1681\/ASN.2017030263","article-title":"Multitarget therapy for maintenance treatment of lupus nephritis","volume":"28","author":"Zhang","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/0961203313502864","article-title":"Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: A 12-month prospective study","volume":"22","author":"Mok","year":"2013","journal-title":"Lupus"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus use in lupus nephritis: A systematic review and meta-analysis","volume":"15","author":"Hannah","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.ajkd.2016.12.008","article-title":"Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: A network meta-analysis of randomized trials","volume":"70","author":"Palmer","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/j.1600-6143.2011.03763.x","article-title":"The PROMISE study: A phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation","volume":"11","author":"Busque","year":"2011","journal-title":"Am J Transplant"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/jcph.237","article-title":"Population PKPD of voclosporin in renal allograft patients","volume":"54","author":"Mayo","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/nm.2497","article-title":"The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension","volume":"17","author":"Hoorn","year":"2011","journal-title":"Nat Med"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.ackd.2005.11.001","article-title":"Calcineurin nephrotoxicity","volume":"13","author":"Williams","year":"2006","journal-title":"Adv Chronic Kidney Dis"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/ndt\/gfv296","article-title":"Histologic versus clinical remission in proliferative lupus nephritis","volume":"32","author":"Malvar","year":"2017","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.13761119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:39Z","timestamp":1786369179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.13761119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.13761119","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]}}}